MedStar Authors catalog › Details for: Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial.
Normal view MARC view ISBD view

Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial.

by Garcia-Garcia, Hector M; Waksman, Ron.
Citation: Clinical Therapeutics. 42(4):649-660.e9, 2020 04.; .Journal: Clinical therapeutics.Published: 2020; ; ; ISSN: 0149-2918.Full author list: BIOFLOW VI Trial Investigators; Gao R; Garcia-Garcia HM; Guan C; Han Y; Li C; Song D; Waksman R; Xu B; Xu J; Yang Y.UI/PMID: 32268942.Subject(s): *Cardiovascular Agents/ad [Administration & Dosage] | *Coronary Artery Disease/th [Therapy] | *Drug-Eluting Stents | *Everolimus/ad [Administration & Dosage] | *Sirolimus/ad [Administration & Dosage] | Aged | Asian Continental Ancestry Group | Female | Humans | Male | Middle Aged | Percutaneous Coronary Intervention | Polymers/ad [Administration & Dosage]Institution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.clinthera.2020.02.014https://dx.doi.org/10.1016/j.clinthera.2020.02.014 (Click here) | (Click here) Abbreviated citation: Clin Ther. 42(4):649-660.e9, 2020 04; .Abstract: FINDINGS: The primary end point of 9-month in-stent late lumen loss (LLL) was 0.05 (0.02) mm in the BP-SES group versus 0.07 (0.02) mm in the DP-EES group, with a mean difference of -0.02 mm (95% CI, -0.06 to 0.03; P = 0.44; Pnoninferiority < 0.0001). At 1 year, the target lesion failure rate (cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization) was similar between the 2 groups (BP-SES 2.3% vs DP-EES 1.4%; P = 0.50). No definite or probable stent thrombosis had occurred in any of the 2 treatment arms.Abstract: IMPLICATIONS: The randomized BIOFLOW-VI trial showed that BP-SES was noninferior to DP-EES with regard to the primary end point of 9-month in-stent LLL in a Chinese population. ClinicalTrials.gov Identifier: NCT02870985. Copyright (c) 2020. Published by Elsevier Inc.Abstract: METHODS: A total of 440 eligible patients from 11 sites with up to 2 de novo native coronary artery lesions were randomly assigned to receive either BP-SES (n = 220) or DP-EES (n = 220) from July 2014 to September 2016 in this prospective, multicenter, noninferiority trial.Abstract: PURPOSE: The BIOFLOW-VI (Biotronik-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With De Novo Coronary Artery Lesions-VI) study evaluates the angiographic efficacy, clinical safety, and effectiveness of the ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP-SES) compared with a durable polymer everolimus-eluting stent (DP-EES). This randomized controlled clinical trial was designed to enable approval of new drug-eluting stents in China.

Powered by Koha